An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

Background: Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC. Methods: Patients received oral suniti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozloff, M., Chuang, E., Starr, A., Gowland, P. A., Cataruozolo, P. E., Collier, M., Verkh, L., Huang, X., Kern, K. A., Miller, K.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890319/
https://www.ncbi.nlm.nih.gov/pubmed/20032126
http://dx.doi.org/10.1093/annonc/mdp565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890319/
https://www.ncbi.nlm.nih.gov/pubmed/20032126
http://dx.doi.org/10.1093/annonc/mdp565

Ejemplares similares